Posted by Site Administrator on December 10, 2012
While some progress has been made in the treatment of ALS, combination therapies with drugs that target other pathways, alongside stem cell technology, are sorely needed
Categories: Clinical Trials, Research News, Treatments
| 
Tags: 20th International Symposium on ALS/MND, 501(c)(3) ALS charity, AAD 2004, Adult stem cells, ALS, ALS community, ALS medical care, ALS research, ALS treatments, ALSFRS-R, AmKor Pharma, amyotrophic lateral sclerosis, anti-inflammatory effects ALS, antioxidative effects ALS, Arimoclomol, Aß plaque, Bensimon, Biogen Idec, Biorex, Bob Stehlin, Brainstorm, BrainStorm Cell Therapeutics, Cell replacement therapies, dexpramipexole, dopamine receptor, Edaravone, Edaravone IV injection, EMPOWER, fast-track status, FDA, FDA fast-track designation, GNDF-producing adult stem cell therapy, GNT Pharma, Hadassah Medical Center, Hadassah Medical Center Israel, hydroxylamine derivative, inhibition and reduction of beta-amyloid (Aß) peptide levels, Knopp Biosciences, lipoperoxide 15-HPETE, Lou Gehrig's disease, Mitsubishi Tanabe Pharma, NCT01281189, NCT01492686, Neuralstem, neuroprotection, NSI 566RSC, NurOwn, Orphazyme ApS, PALS, Phase I trial, Phase II clinical trial, Phase III trial, PNA Center for Neurological Research, pramipexole, Radicut, RASCALS Foundation, Revised ALS Functional Rating Scale, Rilutek, riluzole, Robert A. Stehlin Campaign for ALS, Sanofi, SOD1, Spinal Cord Delivery Platform and Floating Cannula, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis, stem cells, Synthetic Biologics, TCA Cellular Therapy, Tel Aviv University, University of Miami
| 
No comments
Posted by Site Administrator on April 14, 2012
Patients given higher doses got better results. “It was a nice dose-dependent effect,’’ he said. “We didn’t expect that at 12 weeks.’’
Categories: Research News, Treatments
| Tags: Al Sandrock, ALS, ALS community, amyotrophic lateral sclerosis, Biogen Idec, dexpramipexole, George Scangos, Knopp Biosciences, Laura Tuttle, Lou Gehrig's disease, Massachusetts General Hospital, Merit Cudkowicz, mitochondria, RASCALS Foundation, Rilutek, Robert A. Stehlin Campaign for ALS, St.Louis RASCALS ALS Lou Gehrig's Disease amotrophic lateral sclerosis
| No comments
Posted by Site Administrator on January 9, 2012
Results of the first stage showed that receiving dexpramipexole appeared to slow the progression of symptoms measured both by the ALS Functional Rating Scale and by pulmonary capacity. The second stage had similar results, with slower disease progression and a reduced risk of death in participants receiving the higher dosage.
Categories: Research News
| Tags: ALS, ALS community, amyotrophic lateral sclerosis, Biogen Idec, California Pacific Medical Center, Columbia University Medical Center, Craig Amburgey, Dan Moore, David Schoenfeld, dexpramipexole, Donald Archibald, Evan Ingersoll, Hiroshi Mitsumoto, James Mather, Jeremy Shefner, Juliet Moritz, Knopp Biosciences, Lou Gehrig's disease, Mary Sullivan, Massachusetts General Hospital, Massachusetts General Hospital (MGH) Neurology Clinical Trials Unit and ALS Center, Merit Cudkowicz MD, MGH Biostatistics, Michael Bozik, Mitochondrial dysfunction, neurodegenerative disease, Northeast ALS Consortium, Nuedexta, RASCALS Foundation, riluzole, Robert A. Stehlin Campaign for ALS, Robert Miller, State University of New York Upstate Medical University Syracuse, Valentin Gribkoff PhD
| No comments
